Sugarmade Inc (SGMD)

[Mattie711]

Mallen,
IMO- Sound to me that you don't care- but to suggest that Joe Noel is legally running multiple businesses is silly. Documents suggest that JN could be using his wall street background and criminal business experience! Those individuals that are clearly aware of Joe's legal issues are allowing JN to hide. To answer your question- perhaps it's time for the authorities to get involved. I understand that folks are afraid, and perhaps threatened, but this has been going on too long.
All this is just my opinion and I also wanted to provide some factual information.

btw- RE: New Horizon's Laboratory, Inc.-Joe used 2 versions of his name on the initial Wyoming Sec of State filing; Joseph Is Noel, and his electronic signature; Joseph Am Noel. btw- I have copies. Soon after the company was established he removed his name and replaced it with his girlfriend's name; Ma Helen M Im Is. Later, he removed Helen's name and replace it with another. IMO-perhaps he needed this new company because per MCTC/CBGL filing (see below)- New Horizons was about to be compensated by MCTC/CBGL. Later, the compensation outlined in the filing below was changed on a subsequence filing.
I have another list of companies that JN created, or helped create, but I would think that the information below will do for now.

1.Lelantos was registered under Ma Helen M Is Am
2.East West was somehow connected to JC and another guy. I don't know what happened to the company. Probably out of business.
3.Ma Helen IM Is, Inc- is registered to Helen in the state of Wy.
4.New Horizon's Laboratory, I've already covered. It was originally registered by Joseph Is Noel/Joseph AM Noel.

--------------
https://content.edgar-online.com/ExternalLink/EDGAR/0001079974-20-000087.html?hash=3fb74afc94e2515a43524498d670009f73133cc34e3fb05bfa964de38714cc8e&dest=EX10_3_HTM#EX10_3_HTM

"Section 1 - Registrant’s Business and Operations

Item 1.01 Entry into a Material Definitive Agreement.

On February 16, 2020, the Registrant entered into a material definitive agreement (“Agreement”) not made in the ordinary course of its business. The parties to the Agreement are the Registrant and Lelantos Biotech, Inc., a Wyoming corporation (“Lelantos”), Ma Helen M. Am Is, Inc., a Wyoming corporation (“Helen M.”), East West Pharma Group, Inc., a Wyoming corporation (“East West”), and New Horizons Laboratory Services, Inc., a Wyoming corporation (“New Horizons”). There is no material relationship between the Registrant or its affiliates and Lelantos, Helen M., East West, New Horizons, or any of their respective affiliates, other than in respect of the material definitive agreement.

The terms and conditions of the Agreement require the Registrant to issue 400,000 shares of its common stock to Lelantos, and separately, an aggregate of $500,000 in the form of notes payable as follows: $225,000 to Helen M.; $50,000 to East West, $225,000 to New Horizons. The notes are due and payable as follows:

(1) The note to Helen M. is due on June 15, 2020. In the event Registrant defaults on the note, the outstanding amount of principal and interest due converts into 6.75% of the total issued and outstanding shares of Registrant on the maturity date.

(2) The note to East West is due on May 31, 2020 with an interest rate 5% per annum. If Registrant defaults on the note, the interest rate increases to 10%. If Registrant fails to pay by August 30, 2020, the total amount of principal and interest shall be converted into a 1.5% fully diluted ownership of Registrant’s issued and outstanding common shares.

(3) The note to New Horizons is due on May 31, 2020 with an interest rate of 15% per annum. If Registrant defaults on the note, the outstanding amount of principal and interest due converts into 6.75% of the total issued and outstanding shares of Registrant on the maturity date.

In exchange for the foregoing consideration, the Registrant is obtaining all right, title and interest in certain trade secrets, intellectual property rights and research and development, in unique hemp infusion technologies, exotic cannabinoids and nano-fibers that may increase bioavailability and absorption."
-------------------------